Loading...
•
Mar 31, 2025
Sanara MedTech Q1 2025 Earnings Report
posted double-digit revenue growth but widened its net loss amid rising operating expenses
Key Takeaways
Sanara MedTech delivered 26% year-over-year revenue growth in Q1 2025, driven primarily by strong sales of soft tissue repair products. However, the company reported a wider net loss due to increased investments in its Tissue Health Plus segment and corporate infrastructure expansion.
Revenue by Segment
Forward Guidance
Sanara aims to drive continued revenue growth in the Sanara Surgical segment while launching pilot programs and seeking partners for its THP initiative.
Positive Outlook
- Achieved 26% year-over-year revenue growth
- Improved gross margin to 92% from 90% YoY
- Raised $12.25 million in new debt to support expansion
- Sanara Surgical segment Segment Adjusted EBITDA grew by $1.5 million YoY
- Expanded leadership team and product pipeline
Challenges Ahead
- Net loss widened to $3.5 million
- Free cash flow remained negative at nearly $2 million
- Tissue Health Plus segment loss increased significantly
- Operating expenses rose by 30% year-over-year
- Higher interest expense impacted bottom line
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...